Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2020 Feb 14;70(5):943-946.
doi: 10.1093/cid/ciz577.

Elvitegravir-Cobicistat-Emtricitabine-Tenofovir Alafenamide Single-tablet Regimen for Human Immunodeficiency Virus Postexposure Prophylaxis

Pierre Gantner  1   2 , Mojgan Hessamfar  3 , Mohamed Faouzi Souala  4 , Nadia Valin  5 , Anne Simon  6 , Faiza Ajana  7 , Elisabeth Bouvet  8 , Elisabeth Rouveix  9 , Laurent Cotte  10 , Firouzé Bani-Sadr  11 , Laurent Hustache-Mathieu  12 , Marie-Gisèle Lebrette  13 , François Truchetet  14 , Jean-Marie Galempoix  15 , Lionel Piroth  16 , Gérard Pellissier  17 , Patrice Muret  18 , David Rey  19 ; E/C/F/TAF PEP Study Group
Affiliations
Clinical Trial

Elvitegravir-Cobicistat-Emtricitabine-Tenofovir Alafenamide Single-tablet Regimen for Human Immunodeficiency Virus Postexposure Prophylaxis

Pierre Gantner et al. Clin Infect Dis. .

Abstract

We evaluated an elvitegravir-cobicistat-emtricitabine-tenofovir alafenamide single-tablet regimen for human immunodeficiency virus postexposure prophylaxis. The completion rate and adherence were good, and the tolerance was acceptable; no seroconversion was observed. We confirm that this regimen could be appropriate for postexposure prophylaxis.

Clinical trials registration: NCT02998320.

Keywords: HIV; adherence; adverse events; completion; postexposure prophylaxis.

PubMed Disclaimer

Publication types

Associated data